Association of Vitamin B-12 Deficiency with use of metformin in diabetic patients.

DR. Muhammad Zohaib Sadiq
{"title":"Association of Vitamin B-12 Deficiency with use of metformin in diabetic patients.","authors":"DR. Muhammad Zohaib Sadiq","doi":"10.7176/jmpb/68-06","DOIUrl":null,"url":null,"abstract":"Objective: To find out the frequency of vitamin B12 deficiency in patients with type II diabetes mellitus using metformin. Methodology: Ninety two patients were involved after getting informed consent. This cross – sectional study was done at department of Medicine, Nishtar Hospital, Multan. HbA1c, body mass index and blood pressure and deficiency for vitamin B12 was assessed by using electro-chem-iluminescence immunoassay method. B12 levels were categorized as normal (>220pg/ml), possibly deficient (150 to 220 pg/ml) and definitely deficient (<150pg/ml). Neuropathy was assessed and was classified by using Toronto clinical scoring system by the researcher himself. All the data was subjected to statistical analysis using computer software SPSS version 23. Continuous variables were analyzed by their mean and standard deviation while quantitative variables were analyzed by frequency and percentages. Chi square test was applied and P value less than or equal to 0.05 was taken as significant. Results: Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-metformin groups, respectively. The difference was statistically significant (p=0.001). The patients who were possibly deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were significantly more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. The mean Toronto Neuropathy Score was statistically different (p<0.001) between metformin group (6.03±1.73) and non-metformin group (4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 (43.39%) and 5 (9.43%) in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. Statistically, both the groups were significantly different (p=0.005). Conclusion: At the end of this study conclusion can be made that metformin use for type II diabetes mellitus is strongly associated with vitamin B12 deficiency and worsening of already susceptible neuropathy.","PeriodicalId":16339,"journal":{"name":"Journal of Medicine, Physiology and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine, Physiology and Biophysics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7176/jmpb/68-06","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To find out the frequency of vitamin B12 deficiency in patients with type II diabetes mellitus using metformin. Methodology: Ninety two patients were involved after getting informed consent. This cross – sectional study was done at department of Medicine, Nishtar Hospital, Multan. HbA1c, body mass index and blood pressure and deficiency for vitamin B12 was assessed by using electro-chem-iluminescence immunoassay method. B12 levels were categorized as normal (>220pg/ml), possibly deficient (150 to 220 pg/ml) and definitely deficient (<150pg/ml). Neuropathy was assessed and was classified by using Toronto clinical scoring system by the researcher himself. All the data was subjected to statistical analysis using computer software SPSS version 23. Continuous variables were analyzed by their mean and standard deviation while quantitative variables were analyzed by frequency and percentages. Chi square test was applied and P value less than or equal to 0.05 was taken as significant. Results: Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-metformin groups, respectively. The difference was statistically significant (p=0.001). The patients who were possibly deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were significantly more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. The mean Toronto Neuropathy Score was statistically different (p<0.001) between metformin group (6.03±1.73) and non-metformin group (4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 (43.39%) and 5 (9.43%) in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. Statistically, both the groups were significantly different (p=0.005). Conclusion: At the end of this study conclusion can be made that metformin use for type II diabetes mellitus is strongly associated with vitamin B12 deficiency and worsening of already susceptible neuropathy.
糖尿病患者维生素B-12缺乏与二甲双胍使用的关系
目的:了解使用二甲双胍治疗的2型糖尿病患者维生素B12缺乏的发生率。方法:获得知情同意后,纳入92例患者。本横断面研究在木尔坦市尼什塔尔医院内科进行。采用电化学发光免疫分析法测定HbA1c、体重指数、血压及维生素B12缺乏情况。B12水平分为正常(>220pg/ml)、可能缺乏(150 ~ 220pg/ml)和绝对缺乏(<150pg/ml)。神经病变由研究者自行采用多伦多临床评分系统进行评估和分类。所有数据采用SPSS 23版计算机软件进行统计分析。连续变量以均值和标准差分析,定量变量以频率和百分比分析。采用卡方检验,以P值小于等于0.05为显著性。结果:二甲双胍组和非二甲双胍组的平均血清B-12水平分别为378.42±161.27 pg/ml和488.90±147.02 pg/ml。差异有统计学意义(p=0.001)。二甲双胍组可能缺乏和肯定缺乏患者分别为15例(28.30%)和5例(9.43%),显著高于非二甲双胍组4例(10.26%)和0例(p=0.006)。二甲双胍组(6.03±1.73)与非二甲双胍组(4.13±1.75)的平均多伦多神经病评分(Toronto Neuropathy Score)差异有统计学意义(p<0.001)。二甲双胍组有轻度神经病变23例(43.39%)、中度神经病变5例(9.43%),非二甲双胍组有6例(15.38%)、2例(5.13%)。统计学上,两组差异有统计学意义(p=0.005)。结论:二甲双胍治疗II型糖尿病与维生素B12缺乏及易感神经病变加重密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信